John Mulcahy PhD, co-founder and Vice President of Research at SiteOne Therapeutics, has a background in synthetic organic chemistry, drug discovery and neuroscience. As a graduate student, he developed technology to prepare synthetic analogues of natural toxins that are potent, small molecule inhibitors of mammalian voltage-gated sodium ion channels. SiteOne has leveraged this technology, as well as structural insights into the binding pose of the natural toxins, to design novel drug candidates with exquisite selectivity for the human nociceptive sodium channel, NaV1.7, as non-opioid therapeutics for the treatment of pain. John received a PhD in Chemistry from Stanford University and AB in Chemistry, Physics and Classics from Harvard.
ScalmiBio is an early stage company developing transformational technology focusing on oncology applications. We developed a novel technology that converts therapeutic antibodies into a prodrugs activated specifically within tumor. Therapeutics restricting their activity to tumor microenvironment will enable broader use of combination treatments, higher therapeutic doses, and limit side effects.